EP1230270A1 - Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents - Google Patents

Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents

Info

Publication number
EP1230270A1
EP1230270A1 EP00973090A EP00973090A EP1230270A1 EP 1230270 A1 EP1230270 A1 EP 1230270A1 EP 00973090 A EP00973090 A EP 00973090A EP 00973090 A EP00973090 A EP 00973090A EP 1230270 A1 EP1230270 A1 EP 1230270A1
Authority
EP
European Patent Office
Prior art keywords
antibody
biotin
nnoe
affinity
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00973090A
Other languages
German (de)
French (fr)
Inventor
Peter John KS Biomedix Ltd. HARRISON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KS Biomedix Ltd
Original Assignee
KS Biomedix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KS Biomedix Ltd filed Critical KS Biomedix Ltd
Publication of EP1230270A1 publication Critical patent/EP1230270A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • This invention relates to targeting agents, and in particular to antibodies and to their use in targeting anti-tumour agents in vivo. 5 Background to the Invention
  • the conjugate 15 molecular weight of the conjugate.
  • the conjugate for the conjugate to be therapeutically effective, it must be given time to localise at the target site.
  • the radionuclide is therefore present in the body for prolonged periods, and this results in undesirable toxicity at non-target sites.
  • Streptavidin has high affinity for biotin and is able to localise the radionuclide at the target site through the biotin-streptavidin interaction.
  • streptavidin is a protein that is immunogenic in humans, and consequently may not be suitable for repeated, long-term therapeutic use. Summary of the Invention
  • L-biotin i.e. any of the three non-naturally-occurring enantiomers of biotin
  • NOE non-naturally-occurring enantiomer
  • the NNOE can be used to target therapeutic agents to a desired locus in vivo.
  • L-biotin is biologically inactive and therefore, in general, naturally occurring molecules which bind to the NOE or active enantiomer, D-biotin, will not disrupt the targeting of the agent.
  • the NNOE is covalently or otherwise linked to a therapeutic or diagnostic agent, and used to target the agent to a site in vivo.
  • the agent may be a chemotherapeutic agent, e.g. a radiolabelled compound.
  • a further aspect of the invention is an antibody having affinity for the NNOE and not the NOE.
  • the antibody may be a bifunctional antibody, of which one functionality is as described above and the other involves, for example, affinity for a tumour.
  • a novel conjugate comprises an antibody and the NNOE.
  • the conjugate may be administered to a patient to localise the NNOE at a target site. Subsequently, usually after the administration of a clearing agent, an antibody- therapeutic agent conjugate is administered, the antibody having affinity for the NNOE, to localise the agent at the target site.
  • the NNOE molecule is linked to an enzyme that can be used to convert a suitable prodrug into an active cytotoxic form. Description of the Invention
  • NNOE i.e. L-biotin
  • NNOE i.e. L-biotin
  • Antibodies for use in the present invention may be produced using conventional techniques, for example, hybridoma synthesis, recombinant DNA techniques, phage display or other library technology.
  • the antibodies may be derived from any species, including rodent, although it is preferred that the antibodies are derived from mammals other than rodents, e.g. sheep, goats or cows, and have higher affinity.
  • the antibodies will have an affinity of at least 10 10 l/mol, preferably at least 10 11 l/mol, more preferably at least 10 12 l/mol and most preferably at least 10 13 l/mol, e.g. up to 10 15 or 10 16 l/mol, for the respective ligands.
  • a preferred embodiment of the invention is a bifunctional antibody.
  • a bispecific antibody has affinity for the NNOE rather than the NOE, and may also have affinity for a target site.
  • a bispecific antibody allows the use of more potent doses of the active agent, with reduced systemic side-effects.
  • a bifunctional or other antibody according to the invention may be a whole antibody or may be an engineered antibody or a fragment, e.g. f(ab) 2 .
  • the antibody may comprise two single chain fv fragments. The preparation of bifunctional sFvs is well known.
  • the antibodies may be fully human.
  • antibodies for use in the invention may be modified by recombinant DNA techniques to "humanise" them, making them less immunogenic when administered to a patient.
  • a humanised bifunctional antibody should comprise at least the hypervariable region from both a monoclonal antibody having affinity for target antigen, and a monoclonal antibody having affinity for the NNOE.
  • the remainder of the antibody variable region may be of human immunoglobulin.
  • a higher proportion of human immunoglobulin may be present in a whole antibody or a fragment, e.g. F(ab') 2 .
  • the fragment may comprise hypervariable regions as described above and, optionally, the variable framework from human immunoglobulin.
  • the bifunctional antibody will also have affinity for a particular target site.
  • the target site will be a tumour and the antibody will have affinity for a tumour-associated antigen.
  • a tumour-associated antigen is the carcinoembryonic antigen (CEA) which is found on colorectal tumours and other adeno-carcinomas.
  • the NNOE is covalently or otherwise linked to a therapeutic or diagnostic agent.
  • the agent may, for example, be a radionuclide.
  • Administration of the NNOE-radionuclide conjugate will localise the radionuclide at a tumour site through binding to the antibody, to exert a cytotoxic effect on the tumour.
  • Radionuclides having a cytotoxic effect are well known.
  • a preferred radionuclide that may be used in the invention is a radioisotope of phosphorus, yttrium or iodine, e.g. I 123 , I 124 and I 125 which may be used for diagnostic purposes, and l 13 ⁇ Y 90 and P 32 which may be used in therapeutics.
  • Another suitable agent is a cytotoxic drug, e.g. ric or calicheamycin.
  • the NNOE is linked (conjugated) to an enzyme.
  • the enzyme is capable of converting a suitable prodrug into an active cytotoxic form.
  • prodrug is used herein to define an inactive form of a drug which may be cleaved by enzymic action to release the therapeutically-active form.
  • Suitable enzyme- prodrug systems are known to those skilled in the art and include carboxypeptidases and modified mustard gas derivatives.
  • the NNOE targets the enzyme to the target site and subsequent administration of the prodrug will result in the active agent being localised at the target.
  • the antibody and the NNOE-cytotoxic agent may be formulated in a kit, e.g. comprising the two components separately packaged or in separate containers.
  • Each component may be formulated with a suitable carrier or excipient, examples of which are well known, depending on the route of administration, e.g. oral or intravenous.
  • a bispecific antibody is administered, then a clearing agent and then the effector molecule.
  • This sequence, and suitable clearing agents will be familiar to those skilled in the art, e.g. with reference to ADEPT technology; see, for example, Drugs of the Future 1996, 21(2): 167-181 , incorporated herein by reference.
  • the following Example illustrates the invention. In particular, it demonstrates the specificity of an anti D-biotin antibody for D-biotin as compared to L-biotin.
  • the conjugate used was a donkey- anti-sheep antibody conjugated to alkaline phosphatase (A5187, Sigma Chemical, Poole, UK) diluted at 1 :5,000 in 1% BSA in PBS at pH 7.2.
  • PNPP substrate N-2770, Sigma Chemical, Poole, UK
  • the pure D-biotin is more effective at inhibiting the binding of the anti D-biotin monoclonal antibody to immobilised cytochrome C-D-biotin than the racemic mixture that contains both D and L biotins. This confirms that the binding of the antibody to L-biotin is reduced or absent in solution.

Abstract

An antibody that has affinity for a non-naturally-occurring enantiomer (NNOE) of a chiral molecule whose naturally-occurring enantiomer (NOE) is endogenous, and that has no affinity for the NOE, can be used for targeting, in therapy or diagnostic procedures. The antibody may be conjugated to a therapeutic or diagnostic agent, e.g. a cytotoxic agent.

Description

ANTIBODIES BINDING A NON NATURALLY OCCURRING ENANTIOMER (L-BIOTTN) AND THEIR USE AS TARGETING AGENTS
Field of the Invention
This invention relates to targeting agents, and in particular to antibodies and to their use in targeting anti-tumour agents in vivo. 5 Background to the Invention
The targeting of therapeutic agents to particular sites in vivo, is well known. In particular, it is very desirable to target anti-cancer agents to a tumour site, to increase the concentration of the agent at the site and thereby improve its effectiveness in neutralising the tumour. Many agents that target tumours rely on the specificity of
10 monoclonal antibodies for delivering the diagnostic or therapeutic agent to the target site. One approach has been to use a radionuclide-antibody conjugate which localises at a target tissue where the radionuclide may exert its cytotoxic effect.
There are problems with the utility of radionuclide-antibody conjugates, for example poor penetration of the conjugates to the target site owing to the high
15 molecular weight of the conjugate. In addition, for the conjugate to be therapeutically effective, it must be given time to localise at the target site. The radionuclide is therefore present in the body for prolonged periods, and this results in undesirable toxicity at non-target sites.
US-A-5630996 describes the use of antibody-streptavidin conjugates to target
20 a radionuclide-labelled biotin. Streptavidin has high affinity for biotin and is able to localise the radionuclide at the target site through the biotin-streptavidin interaction. However, streptavidin is a protein that is immunogenic in humans, and consequently may not be suitable for repeated, long-term therapeutic use. Summary of the Invention
25 The present invention is based on the realisation that L-biotin, i.e. any of the three non-naturally-occurring enantiomers of biotin, is a suitable ligand for antibody- targeted therapy. More generally, this is true for any endogenous chiral compound, so that any non-naturally-occurring enantiomer (NNOE) can be used, according to this invention. Since neither an anti-NNOE antibody nor the NNOE itself will interact with
30 endogenous/naturally-occurring enantiomer (NOE) or the receptors or carrier proteins for NOEs, the NNOE can be used to target therapeutic agents to a desired locus in vivo. By way of example, L-biotin is biologically inactive and therefore, in general, naturally occurring molecules which bind to the NOE or active enantiomer, D-biotin, will not disrupt the targeting of the agent. According to a further aspect of the invention, the NNOE is covalently or otherwise linked to a therapeutic or diagnostic agent, and used to target the agent to a site in vivo. The agent may be a chemotherapeutic agent, e.g. a radiolabelled compound. Typically, the NNOE will target a site in vivo by interaction with an antibody localised at the target site. Accordingly, a further aspect of the invention is an antibody having affinity for the NNOE and not the NOE. The antibody may be a bifunctional antibody, of which one functionality is as described above and the other involves, for example, affinity for a tumour. Alternatively, a novel conjugate comprises an antibody and the NNOE. The conjugate may be administered to a patient to localise the NNOE at a target site. Subsequently, usually after the administration of a clearing agent, an antibody- therapeutic agent conjugate is administered, the antibody having affinity for the NNOE, to localise the agent at the target site. In another novel conjugate, the NNOE molecule is linked to an enzyme that can be used to convert a suitable prodrug into an active cytotoxic form. Description of the Invention
By way of illustration only, the invention will now be described for a specific NNOE, i.e. L-biotin. This is an example of a preferred NNOE for use in the invention, i.e. is a relatively small, non-toxic organic molecule that exhibits neutral biodistribution in the body, is water/serum-soluble, and is readily excreted by the kidney. It is therefore a suitable molecule for use in targeting therapeutic or diagnostic agents in vivo.
Antibodies for use in the present invention may be produced using conventional techniques, for example, hybridoma synthesis, recombinant DNA techniques, phage display or other library technology. The antibodies may be derived from any species, including rodent, although it is preferred that the antibodies are derived from mammals other than rodents, e.g. sheep, goats or cows, and have higher affinity. Typically, the antibodies will have an affinity of at least 1010 l/mol, preferably at least 1011 l/mol, more preferably at least 1012 l/mol and most preferably at least 1013 l/mol, e.g. up to 1015 or 1016 l/mol, for the respective ligands.
A preferred embodiment of the invention is a bifunctional antibody. A bispecific antibody has affinity for the NNOE rather than the NOE, and may also have affinity for a target site. As part of a multi-step procedure, in which the antibody is administered and allowed to localise before the active agent is given, a bispecific antibody allows the use of more potent doses of the active agent, with reduced systemic side-effects. A bifunctional or other antibody according to the invention may be a whole antibody or may be an engineered antibody or a fragment, e.g. f(ab)2. In a further embodiment, the antibody may comprise two single chain fv fragments. The preparation of bifunctional sFvs is well known. For example, Carter era/., Current Opinion in Biotechnology (1997) 8:449-454, discloses the production of bifunctional sFvs using a phage display library. The antibodies may be fully human. Alternatively, antibodies for use in the invention may be modified by recombinant DNA techniques to "humanise" them, making them less immunogenic when administered to a patient. A humanised bifunctional antibody should comprise at least the hypervariable region from both a monoclonal antibody having affinity for target antigen, and a monoclonal antibody having affinity for the NNOE. The remainder of the antibody variable region may be of human immunoglobulin. A higher proportion of human immunoglobulin may be present in a whole antibody or a fragment, e.g. F(ab')2. When a single-chain Fv fragment is used, the fragment may comprise hypervariable regions as described above and, optionally, the variable framework from human immunoglobulin.
In addition to having affinity for the NNOE, the bifunctional antibody will also have affinity for a particular target site. Typically, the target site will be a tumour and the antibody will have affinity for a tumour-associated antigen. An example of a tumour-associated antigen is the carcinoembryonic antigen (CEA) which is found on colorectal tumours and other adeno-carcinomas.
In a preferred embodiment, the NNOE is covalently or otherwise linked to a therapeutic or diagnostic agent. The agent may, for example, be a radionuclide. Administration of the NNOE-radionuclide conjugate will localise the radionuclide at a tumour site through binding to the antibody, to exert a cytotoxic effect on the tumour. Radionuclides having a cytotoxic effect are well known. A preferred radionuclide that may be used in the invention is a radioisotope of phosphorus, yttrium or iodine, e.g. I123, I124 and I125 which may be used for diagnostic purposes, and l13\ Y90 and P32 which may be used in therapeutics. Another suitable agent is a cytotoxic drug, e.g. ric or calicheamycin. In an alternative embodiment, the NNOE is linked (conjugated) to an enzyme.
The enzyme is capable of converting a suitable prodrug into an active cytotoxic form. The term "prodrug" is used herein to define an inactive form of a drug which may be cleaved by enzymic action to release the therapeutically-active form. Suitable enzyme- prodrug systems are known to those skilled in the art and include carboxypeptidases and modified mustard gas derivatives. The NNOE targets the enzyme to the target site and subsequent administration of the prodrug will result in the active agent being localised at the target.
Methods for attaching therapeutic agents to the NNOE will be apparent to those skilled in the art. For example, procedures for conjugating D-biotin to drugs are known, and can be adopted for the purposes of this invention.
For use in the invention, the antibody and the NNOE-cytotoxic agent may be formulated in a kit, e.g. comprising the two components separately packaged or in separate containers. Each component may be formulated with a suitable carrier or excipient, examples of which are well known, depending on the route of administration, e.g. oral or intravenous.
These two components will usually be administered sequentially. The respective times and durations of administration, and the effective amount of each may readily be determined by the skilled person, and will depend on typical factors such as the location, severity and spread of the tumour, the condition of the subject etc. It is of course a feature of this invention that the amount of cytotoxic agent that is required will be less than in the absence of the antibody.
In a preferred embodiment, a bispecific antibody is administered, then a clearing agent and then the effector molecule. This sequence, and suitable clearing agents, will be familiar to those skilled in the art, e.g. with reference to ADEPT technology; see, for example, Drugs of the Future 1996, 21(2): 167-181 , incorporated herein by reference. The following Example illustrates the invention. In particular, it demonstrates the specificity of an anti D-biotin antibody for D-biotin as compared to L-biotin. Example
Nunc Maxisorb ELISA plates (Nunc, Denmark) were coated with cytochrome C-D-bt. Cytochrome C-D-bt (C2022, Sigma Chemical, Poole, UK) was diluted to 200 ng/ml in PBS at pH 7.2 and 100 μl of this solution added to each well of the plate and incubated for 1 hr at 37°C. Prior to the addition of test samples, the plates were blocked with low fat milk protein. For blocking, the plates were washed 3 times in PBS with 0.01% Tween 20, and 200 μl of 0.2% low fat milk protein was added to each well and incubated at 37 °C for 30 minutes.
Samples of the high affinity sheep monoclonal antibody to D-biotin (1D10, KS Biomedix, UK) were prepared for assay of anti D-biotin activity as follows:
100 μl aliquots of the purified monoclonal antibody at a concentration of 20 ng/ml in 1 % BSA in PBS at pH 7.2 were pre-incubated with various concentrations of either D-biotin or a racemic mixture of D, L-biotin at 37°C for 1 hr prior to addition to the assay plate.
After washing the assay plates as above, the pre-incubated samples were then added to the blocked ELISA plate wells and incubated for 1 hr at 37°C.
After the sample incubation, the plates were washed again and a 100 μl of secondary conjugate was added for 1 hr at 37 °C. The conjugate used was a donkey- anti-sheep antibody conjugated to alkaline phosphatase (A5187, Sigma Chemical, Poole, UK) diluted at 1 :5,000 in 1% BSA in PBS at pH 7.2.
After conjugate incubation, the plates were washed as above and 100 μl of PNPP substrate (N-2770, Sigma Chemical, Poole, UK) added to each well and incubated for 30 minutes at 37°C. The plates were then read at 405 nm in a microtitre plate reader.
The results were as follows:
It can be seen that the pure D-biotin is more effective at inhibiting the binding of the anti D-biotin monoclonal antibody to immobilised cytochrome C-D-biotin than the racemic mixture that contains both D and L biotins. This confirms that the binding of the antibody to L-biotin is reduced or absent in solution.

Claims

I . An antibody (or fragment thereof) having affinity for a non-naturally-occurring enantiomer (NNOE) of a chiral molecule whose naturally-occurring enantiomer (NOE) is endogenous, and which has substantially reduced affinity for the NOE.
2. An antibody according to claim 1, wherein the NNOE is L-biotin and the NOE is D-biotin.
3. An antibody according to claim 1 or claim 2, which is bifunctional.
4. An antibody according to claim 3, which has affinity for a tumour.
5. An antibody according to any preceding claim, wherein the antibody is a Fab fragment or a single-chain Fv.
6. A conjugate of a NNOE (as defined in claim 1 or claim 2) and, covalently linked thereto, a therapeutic or diagnostic agent.
7. A conjugate according to claim 6, wherein the agent is a chemotherapeutic agent.
8. A conjugate according to claim 6 or claim 7, wherein the agent is a radiolabel.
9. A conjugate of a NNOE (as defined in claim 1 or claim 2) and an antibody.
10. A conjugate according to claim 9, wherein the antibody has affinity for a tumour.
I I. Use of an antibody or conjugate according to any of claims 1 to 10, for the manufacture of a medicament for use in the treatment of cancer. 12. A product comprising an antibody according to any of claims 1 to 5 and a conjugate according to any of claims 6 to 10, for simultaneous, sequential or separate use in the treatment of cancer.
EP00973090A 1999-11-09 2000-11-08 Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents Withdrawn EP1230270A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9926529 1999-11-09
GBGB9926529.0A GB9926529D0 (en) 1999-11-09 1999-11-09 Targeting agents
PCT/GB2000/004279 WO2001034651A1 (en) 1999-11-09 2000-11-08 Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents

Publications (1)

Publication Number Publication Date
EP1230270A1 true EP1230270A1 (en) 2002-08-14

Family

ID=10864231

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00973090A Withdrawn EP1230270A1 (en) 1999-11-09 2000-11-08 Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents

Country Status (6)

Country Link
EP (1) EP1230270A1 (en)
JP (1) JP2003513985A (en)
AU (1) AU1164001A (en)
CA (1) CA2389386A1 (en)
GB (1) GB9926529D0 (en)
WO (1) WO2001034651A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014006123A1 (en) * 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Anti-biotin antibodies and methods of use
JP6148729B2 (en) 2012-07-04 2017-06-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Covalently bound antigen-antibody conjugate
KR20150023938A (en) 2012-07-04 2015-03-05 에프. 호프만-라 로슈 아게 Anti-theophylline antibodies and methods of use
KR102278429B1 (en) 2014-01-03 2021-07-16 에프. 호프만-라 로슈 아게 Covalently linked polypeptide toxin-antibody conjugates
MX2016008189A (en) 2014-01-03 2016-09-29 Hoffmann La Roche Covalently linked helicar-anti-helicar antibody conjugates and uses thereof.
JP6476194B2 (en) 2014-01-03 2019-02-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Bispecific anti-hapten / anti-blood brain barrier receptor antibodies, complexes thereof, and their use as blood brain barrier shuttles
CA2947504A1 (en) 2014-06-26 2015-12-30 F. Hoffmann-La Roche Ag Anti-brdu antibodies and methods of use
WO2018122043A1 (en) * 2016-12-27 2018-07-05 F. Hoffmann-La Roche Ag Novel biotin-specific monoclonal antibody and use thereof
WO2018122205A2 (en) * 2016-12-27 2018-07-05 F. Hoffmann-La Roche Ag Novel biotin-specific monoclonal antibody and use thereof
CN111171154B (en) * 2020-02-25 2021-05-11 杭州百凌生物科技有限公司 Anti-biotin antibody and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248611A (en) * 1987-05-28 1993-09-28 Scripps Clinic And Research Foundation Stereoisomer separation method using antibody combing site-containing molecules
US5190865A (en) * 1988-11-18 1993-03-02 The Regents Of The University Of California Antibody-enhanced stereospecific hydrolyses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0134651A1 *

Also Published As

Publication number Publication date
GB9926529D0 (en) 2000-01-12
JP2003513985A (en) 2003-04-15
CA2389386A1 (en) 2001-05-17
AU1164001A (en) 2001-06-06
WO2001034651A1 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
US6077499A (en) Targeted combination immunotherapy of cancer
JP6744212B2 (en) Enzymatic binding of polypeptides
US4937183A (en) Method for the preparation of antibody-fragment conjugates
KR0183980B1 (en) Bispecific and oligospecific mono-and oligovalent receptors, production and applications thereof
US4863713A (en) Method and system for administering therapeutic and diagnostic agents
CN110740754A (en) kinds of anti-mesothelin antibody and antibody drug conjugate thereof
EP1230270A1 (en) Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents
DE60129741T2 (en) TARGETED COMBINATION IMMUNOTHERAPY FOR CANCER AND INFECTION DISEASES
JP2008506355A (en) Anti-human tenascin monoclonal antibody
JP2007512324A (en) Targeting ERB antigen
AU2003217467B2 (en) Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy
US20030215387A1 (en) Bifunctional antibodies and their use in targeting anti-tumour agents
KR20010072988A (en) Bifunctional Antibodies and Their Use In Targeting Anti-tumour Agents
EP0650735A2 (en) Kit and method for pretargeting
AU678474B2 (en) Kit and method for pretargeting
Dennler Microbial Transglutaminase as a Versatile Tool for Site-Specific Protein Modification
CZ2001657A3 (en) Bifunctional antibodies, radiolabelled substance and product formed by antibodies as well as their use for preparing a preparation for treating cancer or for diagnostic methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020610

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20030109